Observational study demonstrates effective treatment for erythematous-telangiectatic rosacea, suggesting an innovative approach.
1200 patients with rosacea, including 525 (43.8%) – with erythematous-telangiectatic subtype were observed during 6 years. An innovative pathogenetic method of treatment of this subtype of rosacea which includes administration of 1% hyaluronic acid in particularly active areas and use of 15% azelic acid in the form of peeling is recognized efficient.
No takes yet. Share an insight, caveat, or question.
PEREVALOVA et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: